Epilepsy and brain tumors

Current Opinion in Oncology

Volumn 22, Issue 6, 2010, Pages 611-620

  Rudà, Roberta ^a   Trevisan, Elisa ^a   Soffietti, Riccardo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

brain tumors; epilepsy; pathogenesis; pharmakoresistance; treatments

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; DACARBAZINE; ERLOTINIB; ETIRACETAM; EVEROLIMUS; FOTEMUSTINE; GABAPENTIN; GEFITINIB; HARKOSERIDE; IMATINIB; LAMOTRIGINE; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE PROTEIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROCARBAZINE; SORAFENIB; TEMOZOLOMIDE; TIAGABINE; TIPIFARNIB; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; ZONISAMIDE;

ACIDOSIS; ADD ON THERAPY; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN HYPOXIA; BRAIN METASTASIS; BRAIN SURGERY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EPILEPSY; EPILEPTOGENESIS; FATIGUE; FOCAL EPILEPSY; FRONTAL LOBE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; GLIOSIS; HISTOLOGY; HUMAN; HYPOTHALAMIC HAMARTOMA; INTRACTABLE EPILEPSY; LIVER METABOLISM; MAGNETOENCEPHALOGRAPHY; MALIGNANT TRANSFORMATION; MENINGIOMA; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROEPITHELIOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL LOBE; PARIETAL LOBE; PATHOGENESIS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOSURGERY; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SHOULDER HAND SYNDROME; SIGNAL TRANSDUCTION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TEMPORAL LOBE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

BRAIN NEOPLASMS; EPILEPSY; HUMANS;

EID: 77958503738     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833de99d     Document Type: Review

References (117)

1. Liigant A, Haldre S, Oun A, et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001; 45:46-51.
2. Lynam LM, Lyons MK, Drazkowski JF, et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 2007; 109:634-638.
3. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6:421-430.
4. Brogna C, Gil Robles S, Duffau H. Brain tumors and epilepsy. Expert Rev Neurother 2008; 8:941-955.
5. Duffau H, Capelle L, Lopes M, et al. Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionectomy. Acta Neurochir 2002; 144:563-572.
6. Luyken C, Blumcke I, Fimmers R, et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003; 44:822-830.
7. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008; 108:227-235.
8. Prayson RA. Diagnostic challenges in the evaluation of chronic epilepsy-related surgical neuropathology. Am J Surg Pathol 2010; 34:e1-e13.
9. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109.
10. Luyken C, Blumcke I, Fimmers R, et al. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 2004; 101:146-155.
11. Majores M, von Lehe M, Fassunke J, et al. Tumor recurrence and malignant progression of gangliogliomas. Cancer 2008; 113:3355-3363.
12. Campos AR, Clusmann H, von Lehe M, et al. Simple and complex dysem-bryoplastic neuroepithelial tumors (DNT) variants: clinical profile, MRI, andhistopathology. Neuroradiology 2009; 51:433-443.
13. Blumcke I, Vinters HV, Armstrong D, et al. Malformations of cortical devel-opment and epilepsies: neuropathological findings with emphasis on focalcortical dysplasia. Epileptic Disord 2009; 11:181-193.
14. Danfors T, Ribom D, Berntsson SG, et al. Epileptic seizures and survival in early disease of grade 2 gliomas. Eur J Neurol 2009; 16:823-831.
15. Schramm J, Luyken C, Urbach H, et al. Evidence for a clinically distinct new subtype of grade II astrocytomas in patients with long-term epilepsy. Neurosurgery 2004; 55:340-347.
16. Kaloshi G, Psimaras D, Mokhtari K, et al. Supratentorial low-grade gliomas in older patients. Neurology 2009; 73:2093-2098.
17. Moots PL, Maciunas RJ, Eisert DR, et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995; 52:717-724.
18. Riva M, Salmaggi A, Marchioni E, et al. Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group. Neurol Sci 2006; 27:345-351.
19. Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res 2000; 38:45-52.
20. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer 2004; 100:2622-2626.
21. Lee JW, Wen PY, Hurwitz S, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol 2010; 67:336-342.
22. Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. Acta Neurochir 2000; 142:1-15.
23. Schaller B, Ruegg SJ. Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 2003; 44:1223-1232.
24. Rajneesh KF, Binder DK. Tumor-associated epilepsy. Neurosurg Focus 2009; 27:E4.
25. Ferrier CH, Aronica E, Leijten FS, et al. Electrocorticographic discharge patterns in glioneuronal tumors and focal cortical dysplasia. Epilepsia 2006; 47:1477-1486.
26. Aronica E, Gorter JA, Redeker S, et al. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy. Neuropathol Appl Neurobiol 2005; 31:280-291.
27. Bartolomei F, Bosma I, Klein M, et al. How do brain tumors alter functional connectivity? A magnetoencephalography study. Ann Neurol 2006; 59:128-138.
28. Bartolomei F, Bosma I, Klein M, et al. Disturbed functional connectivity in brain tumour patients: evaluation by graph analysis of synchronization matrices. Clin Neurophysiol 2006; 117:2039-2049.
29. Ponten SC, Bartolomei F, Stam CJ. Small-world networks and epilepsy: graph theoretical analysis of intracerebrally recorded mesial temporal lobe seizures. Clin Neurophysiol 2007; 118:918-927.
30. Aronica E, Gorter JA, Jansen GH, et al. Expression of connexin 43 and connexin 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol 2001; 101:449-459.
31. Chernov MF, Kubo O, Hayashi M, et al. Proton MRS of the peritumoral brain. J Neurol Sci 2005; 228:137-142.
32. Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 2007; 130:535-547.
33. Marchi N, Angelov L, MasarykT, et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007; 48:732-742.
34. Ricci R, Bacci A, Tugnoli V, et al. Metabolic findings on 3T 1H-MR spectroscopy in peritumoral brain edema. Am J Neuroradiol 2007; 28:1287-1291.
35. Lyons SA, Chung WJ, Weaver AK, et al. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007; 67:9463-9471.
36. Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 2008; 105:287-295.
37. Sontheimer H. An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med 2008; 233:779-791.
38. Aronica E, Yankaya B, Jansen GH, et al. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol 2001; 27:223-237.
39. Maas S, Patt S, Schrey M, et al. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci USA 2001; 98:14687-14692.
40. Lee MC, Kang JY, Seol MB, et al. Clinical features and epileptogenesis of dysembryoplastic neuroepithelial tumor. Childs Nerv Syst 2006; 22:1611-1618.
41. Samadani U, Judkins AR, Akpalu A, et al. Differential cellular gene expression in ganglioglioma. Epilepsia 2007; 48:646-653.
42. Aronica E, Boer K, Becker A, et al. Gene expression profile analysis of epilepsy-associated gangliogliomas. Neuroscience 2008; 151:272-292.
43. Berntsson SG, Malmer B, Bondy ML, et al. Tumor-associated epilepsy and glioma: are there common genetic pathways? Acta Oncol 2009; 48:955-963.
44. Duffau H. New concepts in surgery of WHO grade II gliomas: functional brain mapping, connectionism and plasticity. A review. J Neurooncol 2006; 79:77-115.
45. Zaatreh MM, Firlik KS, Spencer DD, et al. Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome. Neurology 2003; 61:636-641.
46. Choi JY, Chang JW, Park YG, et al. A retrospective study of the clinical outcomes and significant variables in the surgical treatment of temporal lobe tumor associated with intractable seizures. Stereotact Funct Neurosurg 2004; 82:35-42.
47. Bauer R, Dobesberger J, Unterhofer C, et al. Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy. Acta Neu-rochir 2007; 149:1211-1216.
48. Binder DK, Von Lehe M, Kral T, et al. Surgical treatment of occipital lobe epilepsy. J Neurosurg 2008; 109:57-69.
49. Binder DK, Podlogar M, Clusmann H, et al. Surgical treatment of pariet al. lobe epilepsy. J Neurosurg 2009; 110:1170-1178.
50. Phi JH, Kim SK, Cho BK, et al. Long-term surgical outcomes of temporal lobe epilepsy associated with low-grade brain tumors. Cancer 2009; 115:5771-5779.
51. Clusmann H, Schramm J, Kral T, et al. Prognostic factors and outcome after different types of resection for temporal lobe epilepsy. J Neurosurg 2002; 97:1131-1141.
52. Sugano H, Shimizu H, Sunaga S. Efficacy of intraoperative electrocortico-graphy for assessing seizure outcomes in intractable epilepsy patients with temporal-lobe-mass lesions. Seizure 2007; 16:120-127.
53. Kurzwelly D, Herrlinger U, Simon M. Seizures in patients with low-grade gliomas: incidence, pathogenesis, surgical management, and pharmacotherapy. Adv Tech Stand Neurosurg 2010; 35:81-111.
54. Rossi GF, Scerrati M, Roselli R. Epileptogenic cerebral low-grade tumors:effect of interstitial stereotactic irradiation on seizures. Appl Neurophysiol1985; 48:127-132.
55. Warnke PC, Berlis A, Weyerbrock A, et al. Significant reduction of seizure incidence and increase of benzodiazepine receptor density after interstitial radiosurgery in low-grade gliomas. Acta Neurochir Suppl 1997; 68:90-92.
56. Schrottner O, Unger F, Eder HG, et al. Gamma-knife radiosurgery of mesiotemporal tumour epilepsy observations and long-term results. Acta Neurochir Suppl 2002; 84:49-55.
57. Mathieu D, Kondziolka D, Niranjan A, et al. Gamma knife radiosurgery for refractory epilepsy caused by hypothalamic hamartomas. Stereotact Funct Neurosurg 2006; 84:82-87.
58. Kondziolka D, Lunsford LD, Flickinger JC, et al. The application of stereotactic radiosurgery to disorders of the brain. Neurosurgery 2008; 62:707-720.
59. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 1993; 43:1599-1601.
60. Ruda R, Borgognone M, Ducati A, et al. Efficacy of radiation therapy on seizures in low-grade astrocytomas. Neuro-Oncology 2005; 7/3, 7, 422.
61. Chalifoux R, Elisevich K. Effect of ionizing radiation on partial seizures attributable to malignant cerebral tumors. Stereotact Funct Neurosurg 1996; 67:169-182.
62. Van Den Bent MJ, Afra D, De Witte O, et al. EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366:985-990.
63. Soffietti R, Baumert B, Bello L, et al. Guidelines on management of low grade gliomas: report of an EFNS-EANO (European Association for Neuro-Oncology) task force. Eur J Neurol (in press).
64. Mason W, Krol G, De Angelis LM. Lowgrade oligodendroglioma respondsto chemotherapy. Neurology 1996; 46:203-207.
65. Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998; 43:1066-1073.
66. Frenay MP, Fontaine D, Vandenbos F, et al. First-line nitrosourea-based chemotherapy in symptomatic nonresectable supratentorial pure low-grade astrocytomas. Eur J Neurol 2005; 12:685-690.
67. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 2007; 14:391-398.
68. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003; 14:1722-1726.
69. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003; 14:1715-1721.
70. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatments for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1 p deletions. J Clin Oncol 2004; 22:3133-3138.
71. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007; 68:1831-1836.
72. Taillandier L, Duffau H. Epilepsy and insular grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases. Neurosurg Focus 2009; 27:E8.
73. Soffietti R, Ruda R, Trevisan E, et al. Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: a phase II AINO study. J Clin Oncol 2008; 26 [abstract 2019].
74. Franz DN, Krueger M, Care M, et al. Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS). J Clin Oncol 2010; 28:180S.
75. Avila EK, Graber J. Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep 2010; 10:60-67.
76. Vecht CJ, Wilms EB. Seizures in low-and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther 2010;10:663-669.
77. Vecht CJ, Van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006; 67:S10-S13.
78. Hildebrand J, Lecaille C, Perennes J, et al. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005; 65:212-215.
79. Perry JR, Sawka C. Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 1996; 23:128-131.
80. StrianoS, Striano P, Boccella P, et al. Tiagabine in glial tumors. Epilepsy Res 2002; 49:81-85.
81. Wagner GL, Wilms EB, Van Donselaar CA, et al. Levetiracetam: preliminary experience in patients with primary brain tumors. Seizure 2003; 12:585-586.
82. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 2006; 78:99-102.
83. Maschio M, Albani F, Baruzzi A, et al. Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 2006; 80:97-100.
84. Maschio M, Dinapoli L, Zarabla A, et al. Outcome and tolerability of topir-amate in brain tumor associated epilepsy. J Neurooncol 2008; 86:61-70.
85. Novy J, Stupp R, Rossetti AO. Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 2009; 111:171-173.
86. Maschio M, Dinapoli L, Saveriano F, et al. Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. Acta Neurol Scand 2009; 120:210-212.
87. Rosati A, Buttolo L, Stefini R, et al. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol 2010;67:343-346.
88. Newton H, Connelly J, Lima J, et al. Lacosamide in brain tumour patients with refractory seizures: efficacy and tolerability. J Neurol 2010; 257:476.
89. Haghikia A, Ladage K, Hinkerohe D, et al. Implications of antiinflammatory properties of the anticonvulsant drug levetiracetam in astrocyties. J Neurosci Res 2008; 86:1781-1788.
90. Meador KJ. Cognitive effects of levetiracetam versus topiramate. Epilepsy Curr 2008; 8:64-65.
91. Moots PL, Maciunas RJ, Eisert DR, et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995; 52:717-724.
92. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002; 14:299-307.
93. Glantz Mj, Cole BF, Forsyth PA, et al. Practice parameters: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000; 54:1886-1893.
94. Klein M, Engelberts NH, Van Der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 2003; 54:514-520.
95. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2:473-481.
96. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2:404-409.
97. Yap KY, Tay WL, Chui WK, et al. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008; 30:1385-1407.
98. Maschio M, Albani F, JandoloB, et al. Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. J Neurooncol 2008; 90:217-221.
99. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity and patterns of recurrence. Neurology 2008; 70:779-787.
100. Butowski NA, Chang SM. General and neurological complications of targeted therapy. In Grisold W, Soffietti R, editors. 'Neuro-oncology', handbook of clinical neurology 2010 (in press).
101. Bourg V, Lebrun C, Chichmanian RM, et al. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001; 12:217-219.
102. Oberndorfer S, Piribauer M, Marosi C, et al. P450 enzyme inducing and nonenzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005; 72:255-260.
103. Jaeckle KA, Ballman K, Furth A, et al. Correlation of enzyme-inducing antic-onvulsant use with outcome of patients with glioblastoma. Neurology 2009;73:1207-1213.
104. Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizures prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004; 79:1489-1494.
105. Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:97-102.
106. Tremont-Lukats IW, Ratilal BO, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Rev The Cochrane Library 2009; 1-20 [Wiley].
107. Siomin V, Angelov L, Vogelbaum MA. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of antiepilepsy drugs in patients with brain tumors. J Neuro-Oncol 2005; 74:211-215.
108. Mauro AM, Bomprezzi C, Morresi S, et al. Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J Neurooncol 2007; 81:279-285.
109. Milligan TA, Hurwitz S, Bromfield EM. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008; 71:665-669.
110. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresis-tance to antiepileptic drugs. J Pharmacol Exp Ther 2002; 301:7-14.
111. Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drugs resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 2005; 74:113-121.
112. Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy; focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003; 118:417-429.
113. Bauer B, Hartz AM, Pekcec A, et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclo-oxygenase-2 signaling. Mol Pharmacol 2008; 73:1444-1453.
114. Loscher W. Drug transporters in the epileptic brain. Epilepsia 2007; 48:8-13.
115. Baltes S, Fedrowitz M, Tortos CL, et al. Valproic acid is not a substrate for P-glycoproyein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007; 320:331-343.
116. Tang R, Faussat AM, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004; 18:1246-1251.
117. Kannan P, John C, Zoghbi SS, et al. Imaging the function of P-Glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin PharmacolTher 2009; 86:368-377.